

Box Seg A

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No.	UCSD0-078-2
First Inventor or Application Identifier	EDWARD A. DENNIS
Title	CLONED HUMAN LYSOPHOSPHOLIPASE
Express Mail Label No.	EJ079900564US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
- ☒ Specification [Total Pages **28**]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **10**]
- Oath or Declaration [Total Pages **2**]
 - ☒ Newly executed (original or copy)
 - ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- ☐ Microfiche Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☒ Computer Readable Copy
 - ☒ Paper Copy (identical to computer copy)
 - ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☒ Assignment Papers (cover sheet & document(s))
- ☐ 37 C.F.R. § 3.73(b) Statement of Power of Attorney (when there is an assignee) ☒
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- ☒ * Small Entity Statement(s) filed in prior application, Status still proper and desired (PTO/SB/09-12)
- ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
- ☐ Other: _____

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____
Prior application information: Examiner _____ Group / Art Unit: _____
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)	or <input checked="" type="checkbox"/> Correspondence address below	
Name	FUESS & DAVIDENAS		
Address	10951 SORRENTO VALLEY RD., STE. II-G		
City	SAN DIEGO	State	CA
Country		Zip Code	92121
	Telephone	858 452-8293	Fax 858 452-6035

Name (Print/Type)	William C. Fuess	Registration No. (Attorney/Agent)	30,054
Signature	William C. Fuess	Date	01/29/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

CERTIFICATION UNDER 37 CFR 1.10

EXPRESS MAIL


I hereby certify that this Correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" mailing Label Number: EJO79900564US

addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date typed below.

1/28/00
Date

Joseph Davidenas

Typed Name of Person
Mailing Correspondence
and Documents


Signature of Person
Mailing Correspondence
and Documents

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Edward Dennis
Attorney's Docket No.: UCSD0-078-2
Title: CLONED HUMAN LYSOPHOSPHOLIPASE
UCSD Case No.: SD98-078-2


VERIFIED STATEMENT UNDER 37 CFR §1.9(d) AND §1.27(d)
CLAIMING STATUS AS A SMALL ENTITY - NONPROFIT ORGANIZATION

I, Dr. Alan Paau, Director of the Technology Transfer Office of the University of California, San Diego, hereby declare that:

1. I am empowered to act on behalf of THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a corporation duly organized under and pursuant to the laws of CALIFORNIA having its principal place of business at 1111 Franklin Street, 5th Floor, Oakland California 94607-5200, in the matter of this VERIFIED STATEMENT.
2. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA is a University of higher education of the State of California and a nonprofit organization.
3. ~~The rights under contract or law in the invention contained within the above identified patent application are obligated to be assigned to and remain with THE REGENTS OF THE UNIVERSITY OF CALIFORNIA. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license any rights in the invention nor in the application to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR §1.9(d) or a non-profit organization under 37 CFR §1.9(e).~~
4. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA qualifies as a nonprofit organization as defined in 37 CFR §1.9(e) for paying reduced fees under section 41 subsections (a) and (b) of Title 35, United States Code, with regard to said application.
5. I acknowledge the duty under 37 CFR §1.28(b) to file, in this application or any patent issuing thereon, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of any issuance fee or any maintenance fee due after that date on which status as a small entity is no longer appropriate.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent(s) issuing thereon.

1/27/00
Date


Signature of Alan Paau, MBA, Ph.D.
Director, Technology Transfer Office
University of California San Diego
9500 Gilman Drive, MC 0910
La Jolla, CA 92093-0910
Representative of THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

**APPLICATION FOR
UNITED STATES PATENT**

IN THE NAME OF

EDWARD A. DENNIS

AND

AIJUN WANG

FOR

CLONED HUMAN LYSOPHOSPHOLIPASE

**Joseph A. Davidenas, Ph.D., J.D.
FUESS & DAVIDENAS
10951 Sorrento Valley Rd., Ste. II-G
San Diego, CA 92121**

Attorney Docket: UCSD9-003-1

Date of Deposit: 12/09/99

CLONED HUMAN LYSOPHOSPHOLIPASE

5

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to enzymes that hydrolyze lysophospholipids in tissues.

The present invention particularly concerns a new, cloned human brain
10 lysophospholipase, its kinetic parameters and of its potential role in treatment of disease states having elevated concentrations of lysophospholipids, including atherosclerosis, hyperlipidemia, lethal dysrhythmias in myocardial ischemia and segmental demyelination of peripheral nerves.

15 Description of Related Art

Lysophospholipases (LysoPLA) are important enzymes that hydrolyze
lysophospholipids (LysoPL). LysoPLs are detergent-like intermediates in phospholipid
metabolism and play essential roles in many physiological and pathological processes.
Lysophosphatidylcholine (LysoPC), a normal constituent of cell membranes, may act as a
20 lipid messenger, transducing signals initiated from membrane receptors. Exogenous addition of LysoPC to cultured cells regulates the expression and/or activity of a variety of proteins including nitric oxide synthase, IL-1 β , transcription factor nuclear factor-kappa B, activator protein 1, c-Jun N-terminal kinase, heparin-binding epidermal growth factor-like growth factor, cellular adhesion molecule-1 and many other proteins. LysoPC also modulates
25 intracellular Ca²⁺ levels, stimulates the release of arachidonic acid in human endothelial cells and rat mesangial cells through a pathway that involves the activation of PKC and cPLA2. Lysophosphatidic acid (LPA), the simplest natural occurring LysoPL, is a multifunctional phospholipid messenger that evokes a variety of biological responses, ranging from platelet

aggregation to smooth muscle contraction, from cell proliferation and differentiation to focal adhesion assembly and stress fiber formation. Such diversified biological responses to LPA appear to involve the activation of a specific G-protein coupled receptor, which in turn couples to multiple independent effector pathways including the small GTP-binding proteins Ras and Rho. Indeed, LPA-specific receptors were cloned recently and identified as members of the G-protein coupled receptors. Increased LysoPL levels have been detected in a variety of disease states including atherosclerosis, hyperlipidemia, lethal dysrhythmias in myocardial ischemia and segmental demyelination of peripheral nerves. Accumulation of LysoPL can perturb the activities of many membrane-bound signal-transducing enzymes, distort cell membrane integrity and even lead to cell lysis.

These increased LysoPL levels are believed to result from the dysfunction of LysoPL-regulating enzymes. Since LysoPLs play such diversified roles, their levels must be strictly regulated for proper cell function and survival. LysoPLA, which controls LysoPL levels through hydrolysis, has been identified in a variety of cells and tissues. Recently, a rat and a mouse LysoPLA have been sequenced, cloned and expressed. These two enzymes (both of 25 kDa molecular mass) share high sequence homology and exhibit similar properties. They are new members of the K/L hydrolase family with a catalytic site composed of Ser-119, Asp-174 and His-208.

SUMMARY OF THE INVENTION

The present invention contemplates a cDNA segment encoding a lysophospholipid-specific human lysophospholipase enzyme protein molecule having 690 deoxyribonucleotide base pairs from position 48 to position 741 of SEQ ID NO:1, as shown in Figure 1, and modifications thereof that encode active human lysophospholipase molecules.

More preferably, the invention contemplates a deoxyribonucleic acid sequence for a

cDNA segment encoding a lysophospholipid-specific human brain lysophospholipase enzyme protein molecule, having a sequence of 690 deoxyribonucleotide base pairs from position 48 to position 741 of SEQ ID NO:1, as shown in Figure 1, and modifications thereof that encode active human lysophospholipase molecules.

The present invention also contemplates a recombinant lysophospholipid-specific human brain lysophospholipase enzyme protein molecule, having a single 25kDa polypeptide of 230 amino acid residues in length, and a catalytic activity site triad at Ser-119, Asp-174 and His-208, and active modifications thereof.

More preferably, an amino acid residue sequence for a recombinant lysophospholipid-specific human brain lysophospholipase enzyme protein molecule having amino acid residues from amino acid residue position 1 to amino acid residue position 230, of SEQ ID NO: 2, as shown in Figure 1, and active modifications thereof.

The present invention further relates to a contemplated method of inhibiting catalytic activity of a recombinant lysophospholipid-specific human brain lysophospholipase enzyme protein molecule by exposing the lysophospholipase enzyme protein molecule to a solution containing methyl arachidonyl fluorophosphates.

In the most preferred embodiment, the inhibiting that results from the exposing is irreversible.

In another, most preferred embodiment, is contemplated a method for treating subjects with diseases caused by increased levels of lysophospholipids, the method comprising supplying a recombinant lysophospholipid-specific lysophospholipase enzyme to an enzyme-deficient subject. The method of supplying can be administered by infusion. More

preferably, the supplying is by gene augmentation therapy.

Still further embodiments and advantages of the invention will become apparent to those skilled in the art upon reading the entire disclosure contained herein.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. shows the cDNA and translated amino acid sequences of human brain LysoPLA. The cDNA and amino acid residues that are different between the human and mouse enzymes are in bold, the catalytic triad is marked by *. The primers that were used to clone the human enzyme are indicated by the lines above the cDNA sequences, and the sequences refer to the sequences in the experimental procedures. The 5' and 3' untranslated cDNA sequences were obtained from GenBank.

Figure 2. is a depiction of SDS-PAGE of human brain. LysoPLA. Human recombinant LysoPLA (28 kDa) was strongly induced by IPTG in *E. coli* transformed with PET28a+/hLysoPLA (lane 2), as compared to that of *E. coli* before IPTG induction (lane 1). Lane 3 is the purified human recombinant LysoPLA with the His•Tag attached, and lane 4 shows the protein with the His•Tag removed by thrombin digestion as demonstrated by the protein band shift.

Figure 3. demonstrates the activity of human LysoPLA as a function of LysoPC concentration. The substrate was prepared as a 20 U concentrated suspension, then diluted in the assay buffer to the desired final concentration, as indicated. 140 ng of recombinant human brain LysoPLA were added to the 1 U substrate to start the reaction at 40°C for 2, 5 or 10 min. The specific activity of lysophospholipase for each substrate concentration was obtained from the activity (nmol/mg) vs. time plot. Data were fit to Michaelis-Menten equation (dotted line) and

to Hill model (solid line). Each data point represents an average of three independent experiments, each in triplicate.

Figure 4. is a kinetic analysis of human recombinant LysoPLA. LysoPLA activity was determined as a function of the mol% of LysoPC achieved either by fixing the LysoPC (1.125 mM) and varying the TX-100 concentration (A), or by fixing TX-100 (1 mM) and varying the LysoPC substrate concentration (B), or by fixing the mole fraction (surface concentration) of LysoPC, as indicated by the numbers in C. Each data point represents an average of four determinations in A, and an average of two independent experiments, each in triplicate in B and C. Data in A and B were fitted assuming Michaelis-Menten kinetics, and the inserts are the linear fits of the double reciprocal plots. Lines in C are the global fits using Equation 1.

Figure 5. demonstrates inhibition of human recombinant LysoPLA by MAFP. LysoPLA activity was assayed in the presence of different concentrations of MAFP, and expressed as percentage of the activity in the absence of the inhibitor. The data were fit to a single exponential decay.

Figure 6A. refers to the tissue distribution of human LysoPLA in the heart, brain, placenta, lung, liver skeletal muscle, kidney and pancreas (lanes 1 - 8 respectively).

Figure 6B. refers to the tissue distribution of human LysoPLA mRNA for more specific brain regions, glands and tissues shown in Figure 6B.

Figure 6C. refers to the textual description of the tissue distribution of human LysoPLA as exemplified in Figure 6B.

Figure 6D. is a Western blot showing the protein levels of LysoPLA in 70 μ of protein from

human brain, heart, liver, lung kidney, testis, ovary and placenta (lanes 1 -8 respectively) 5ng of purified recombinant human LysoPLA is in lane 9 as a control.

DETAILED DESCRIPTION OF THE INVENTION

5 Abbreviations

	BEL	bromoenol lactone;
	BSA	bovine serum albumin;
	cPLA2	cytosolic Ca ²⁺ -dependent phospholipase A2;
	DPPC	1-palmitoyl-2-palmitoyl-sn-glycero-3-phosphorylcholine;
10	hLysoPLA	human lysophospholipase;
	iPLA2	Ca ²⁺ -independent phospholipase A2
	IPTG	isopropyl thio-L-D-galactoside;
	LysoPC	1-palmitoyl-sn-glycero-3-phosphorylcholine;
	LysoPL	lysophospholipid;
15	Lme	L-mercaptoethanol;
	MAFP	methyl arachidonyl fluorophosphonate;
	mLysoPLA	mouse lysophospholipase;
	PACOCF3	palmitoyl trifluoromethyl ketone;
	PAPC	1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine;
20	PCR	polymerase chain reaction;
	PIP2	phosphatidylinositol 4,5-bisphosphate;
	PlsCho	plasmerylcholine (1-O-(Z)-1 P -alkenyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine);
	TX-100	Triton X-100

25

Definition of Terms

Amino Acid: All amino acid residues identified herein are in the natural L-configuration. In keeping with standard polypeptide nomenclature, *J. Biol. Chem.*, 243:3557-59, (1969), abbreviations for amino acid residues are as shown in the following Table of

30 Correspondence:

TABLE OF CORRESPONDENCE

	<u>1-Letter</u>	<u>SYMBOL</u> <u>3-Letter</u>	<u>AMINO ACID</u>
5	Y	Tyr	L-tyrosine
	G	Gly	glycine
	F	Phe	L-phenylalanine
	M	Met	L-methionine
	A	Ala	L-alanine
10	S	Ser	L-serine
	L	Ile	L-isoleucine
	L	Leu	L-leucine
	T	Thr	L-threonine
	V	Val	L-valine
15	P	Pro	L-proline
	K	Lys	L-lysine
	H	His	L-histidine
	Q	Gln	L-glutamine
	E	Glu	L-glutamic acid
20	W	Trp	L-tryptophan
	R	Arg	L-arginine
	D	Asp	L-aspartic acid
	N	Asn	L-asparagin
	C	Cys	L-cysteine
25			

It should be noted that all amino acid residue sequences are represented herein by formulae whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a bond to a radical such as H and OH (hydrogen and hydroxyl) at the amino- and carboxy-termini, respectively, or a further sequence of one or more amino acid residues up to a total of about fifty residues in the polypeptide chain. specific.

Base Pair (bp): A partnership of adenine (A) with thymine (T), or of cytosine (C) with guanine (G) in a double stranded DNA molecule.

Constitutive promoter: A promoter where the rate of RNA polymerase binding and

initiation is approximately constant and relatively independent of external stimuli. Examples of constitutive promoters include the cauliflower mosaic virus 35S and 19S promoters described by Poszkowski et al., *EMBO J.*, 3:2719 (1989) and Odell et al., *Nature*, 313:810 (1985).

5 **DNA:** Desoxyribonucleic acid.

Enzyme: A protein, polypeptide, peptide RNA molecule, or multimeric protein capable of accelerating or producing by catalytic action some change in a substrate for which it is often specific.

Expression vector: A DNA sequence that forms control elements that regulate
10 expression of structural genes when operatively linked to those genes.

Expression: The combination of intracellular processes, including transcription and translation undergone by a structural gene to produce a polypeptide.

Insert: A DNA sequence foreign to the rDNA, consisting of a structural gene and optionally additional DNA sequences.

15 **Nucleotide:** A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and that combination of base and sugar is a nucleoside. When the nucleoside contains a phosphate group bonded to the 3' or 5' position of the pentose it is referred to as a nucleotide.

20 **Operatively linked or inserted:** A structural gene is covalently bonded in correct reading frame to another DNA (or RNA as appropriate) segment, such as to an expression vector so that the structural gene is under the control of the expression vector.

Polypeptide and peptide: A linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.

25 **Promoter:** A recognition site on a DNA sequence or group of DNA sequences that provide an expression control element for a gene and to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene.

Inducible promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include light, heat, anaerobic stress, alteration in nutrient conditions, presence or absence of a metabolite, presence of a ligand, microbial attack, wounding and the like.

5 **Spatially regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism such as the leaf, stem or root. Examples of spatially regulated promoters are given in Chua et al., *Science*, 244:174-181 (1989).

10 **Spatiotemporally regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism at a specific time during development. A typical spatiotemporally regulated promoter is the EPSP synthase-35S promoter described by Chua et al., *Science*, 244:174-181 (1989).

15 **Temporally regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated at a specific time during development. Examples of temporally regulated promoters are given in Chua et al., *Science*, 244:174-181 (1989).

Protein: A linear series of greater than about 50 amino acid residues connected one to the other as in a polypeptide.

Recombinant DNA molecule: A hybrid DNA sequence comprising at least two nucleotide sequences not normally found together in nature.

20 **RNA:** Ribonucleic acid.

Selective Genetic marker: A DNA sequence coding for a phenotypical trait by means of which transformed cells can be selected from untransformed cells.

Structural gene: A DNA sequence that is expressed as a polypeptide, i.e., an amino acid residue sequence.

25 **Synthetic promoter:** A promoter that was chemically synthesized rather than biologically derived. Usually synthetic promoters incorporate sequence changes that optimize the efficiency of RNA polymerase initiation.

1. Introduction

This invention discloses the cloning, expression and purification of the human LysoPLA (hLysoPLA). The substrate specificity, kinetics and inhibition of pure hLysoPLA was examined. Recently, it was reported that a similar rabbit LysoPLA also functioned as a PLA2 to hydrolyze plasmenylcholine, which is abundant in heart and brain; this is not the case for the human enzyme. Furthermore, the tissue and regional distribution patterns of the enzyme have been characterized herein.

2. Experimental Design, Materials and Methods

2.1. Cloning of human LysoPLA

Human brain messenger RNA (Clontech) was used to synthesize first-strand cDNA at 37°C for 1 h using Moloney murine leukemia virus reverse transcripts (Stratagene) and random primers (Promega). Aliquots of the first-strand cDNA were used to amplify the hLysoPLA gene by PCR using Taq DNA polymerase (Promega). The sequences of the primers used in the PCR cycles were: 5' P -GGG GGG CAT ATG TGC GGC AAT AAC ATG TCA ACC CC-3' P and 5' P -GCG CGA ATT CTC AAT CAA TTG GAG GTA GGA GTT TAT-3' P. These primers were designed based on the human sequences found in the GenBank using the mouse LysoPLA sequence as the probe. Restriction enzyme sites (NdeI and EcoRI) were included near the 5' P -ends to facilitate directional cloning (see Fig. 1).

The PCR cycles were performed by preheating at 95°C for 1 min, then five cycles of denaturation at 95°C for 45 s, annealing at 60°C for 1 min and extension at 72°C for 2 min. This was followed by 25 cycles of 95°C for 45 s, 66°C for 1 min and 72°C for 2 min. Finally, the PCR product was extended at 72°C for 10 min. The amplified PCR product was about 700 bp, and was purified from a 1% agarose gel using Wizard™ PCR Preps (Promega).

To clone the human gene, the purified PCR product was ligated into the pCR2.1

vector (Original TA Cloning Kit from Invitrogen) using T4 DNA ligase (Pharmacia) at 14°C for 19 h. The ligase was heat-inactivated by incubating at 70°C for 10 min. The ligation product was used to transform *Escherichia coli* INVKF P cells, and then plated on LB-Amp (100µg/ml) with X-Gal. After incubation overnight at 37°C and then 6 h at 4°C, several

5 white colonies were selected for overnight cultures in LB-Amp(100 µg/ml). The plasmids prepared from the over-night cultures were screened by restriction enzyme analysis using *EcoRI* and *NdeI* (Pharmacia). A majority of the screened colonies contained the vector with the correct size insert. The DNA sequence of the insert was obtained using an automated DNA sequencer (Applied Biosystems 373 from Perkin-Elmer). To subclone hLysoPLA from

10 the pCR2.1 vector into the protein expression vector pET28a(+) (Novagen), both the pET28a(+) and the pCR2.1/hLyso-PLA vectors were digested with *NdeI* and *EcoRI*, and then separated on 1% agarose gels. The bands corresponding to hLysoPLA (approx. 700 base pairs) and pET28a(+) (approx. 5300 base pairs) were purified and ligated as described hereinabove. The ligation product was used to transform competent *E. coli* NovaBlue cells

15 (Novagen), and the resulting colonies were screened. It should be noted that the cloned hLysoPLA has an extra 20 amino acids at the N-terminus of the protein, the sequence of which is shown in Sequence 1:

20 Sequence 1:

MGSSHHHHHHSSGLVPR↓GSH — hLysoPLA

His-Tag thrombin site

As indicated above, the His-Tag can be removed by thrombin cleavage, leaving three extra amino acids at the N-terminus of the protein.

25

2.2. Expression and purification of hLysoPLA protein

The pET28a(+)/hLysoPLA was used to transform competent *E. coli* BL21(DE3) (Novagen), and a single colony was inoculated in an overnight culture in LB-kanamycin (50

5 $\mu\text{g/ml}$) medium. This overnight culture was then diluted 40-fold into Terrific broth-
 kanamycin (50 $\mu\text{g/ml}$) medium, and allowed to grow at 37°C until the A600 nm reached 1.
 Then, IPTG (Fisher) was added to a final concentration of 0.4 mM and the cells were grown
 at 22°C for an additional 5 h to induce foreign protein expression. Finally, the *E. coli* cells
 were centrifuged and the pellet was stored at 32°C. The purification procedures were carried
 out at 4°C, as described previously.

10 Briefly, the *E. coli* pellet was resuspended in lysis bujer (25 mM Tris- HCl, pH 8.0,
 500 mM NaCl, 5 mM imidazole and 10 mM LMe) and digested by lysozyme (Sigma). The
 mixture was sonicated and centrifuged at 100,000 U g for 45 min. The supernatant was passed
 through a Ni-NTA column (Qiagen), the column washed with lysis bujer, and the protein
 eluted with elution buffer (25 mM Tris-HCl, pH 8.0, 500 mM NaCl, 250 mM imidazole and
 10 mM LMe). The eluted hLysoPLA was then loaded onto a Sephadex G-75 (2.5 U 90 cm,
 Pharmacia) column equilibrated in buffer containing 10 mM each of Tris-HCl (pH 8.0), NaCl
 15 and LMe. The hLysoPLA that eluted from the G-75 column was essentially homogeneous.
 The His W Tag was removed by digestion with biotinylated thrombin (Novagen) overnight at
 4°C. The biotinylated thrombin was removed at the end of the digestion by streptavidin
 agarose (Novagen), and the cleaved His W Tag removed by dialysis against 10 mM each of
 Tris (pH 8.0) and LMe. The enzyme was stored at 32°C after glycerol was added to a final
 20 concentration of 50% and LMe to 10 mM.

2.3. Northern blot

25 The 32 P-labeled probe was prepared by incubating 50 ng cDNA of hLysoPLA with
 50 μCi [32 P]dCTP (DuPont-NEN) and Ready-To-Go DNA labeling beads (-dCTP)
 (Pharmacia Biotech) at 37°C for 15 min, as described by the protocol supplied by the
 manufacturer. The 32 P-labeled cDNA probe was purified through a ProbeQuant G-50
 microcolumn (Pharmacia Biotech). The human RNA blot (Clone- tech) was prehybridized

with 20 ml of ExpressHyb solution (Clontech, CA) containing 1 mg/ml salmon sperm DNA at 65°C for 30 min. The RNA blot was hybridized with 5 ml of ExpressHyb containing 6 µg/ml of human Cot-1 DNA, 30 µg/ml of salmon sperm DNA, 0.2 U SSC (sodium chloride and sodium citrate) and 10⁷ cpm of human lysophospholipase cDNA probe (with specific activity of 1.5 U 10⁹ cpm/µg) overnight at 65°C. After hybridization, the membrane was washed once with 200 ml of 2 U SSC containing 1% SDS at 65°C for 20 min, and twice with 0.1 U SSC containing 0.5% SDS at 55°C for 20 min each. The membrane was exposed to X-ray film for 24 h at 37°C. After developing, the film was read with a densitometer and each dot was quantitated.

2.4. Western blot

The tissue distribution pattern of hLysoPLA at the protein level was examined by Western blot analysis using rabbit antibody (customer-made by HTI BioProducts) raised against purified recombinant hLyso-PLA. First, 70 µg of protein from different human tissues (Clontech) were separated by 12% SDS- PAGE along with prestained protein molecular weight markers (Bio-Rad) and pure hLysoPLA. The proteins in the gel were then transferred to a PVDF membrane (Millipore). To block any non-specific binding, the membrane was incubated first in 5% non-fat milk in PBS (phosphate-buffered saline), followed by rabbit pre-immune serum (1/1000 dilution with PBS containing 0.5% Tween 20 and 0.5% milk) for 1 h. The protein bands recognized by the preimmune serum were visualized and blocked by treating the membrane with horseradish peroxidase-conjugated protein A (Amersham) and VECTOR SG substrate kit for peroxidase (Vector Laboratories). Then, the membrane was probed with the rabbit anti-hLysoPLA serum (1/1000 dilution) for 1 h, followed by horseradish peroxidase-conjugated protein A (Amersham). Finally, the protein bands were detected by the ECL system (Amersham).

2.5. LysoPLA activity, PLA2 activity and protein purity determination

The protein concentration was determined by the Bio-Rad protein assay, using bovine serum albumin (BSA) as standard. Protein purity was examined using 12% SDS-PAGE and Coomassie blue staining. LysoPLA activity was measured at 40°C in the assay buffer containing LysoPC, 100 mM Tris-HCl (pH 8.0) and 10 mM LMe. Cold 1-palmitoyl-sn-glycero-3-phosphorylcholine (125 µM, unless indicated otherwise) was mixed with 1-[¹⁴C]palmitoyl-sn-glycero-3-phosphorylcholine (100,000 cpm) in a total volume of 0.5 ml. The assay was initiated by adding an aliquot of enzyme solution to the substrate mixture and incubating for the desired time. The released fatty acid was extracted by the modified Dole method and then quantified by scintillation counting. The PLA2 activity assay was carried out, using various ¹⁴C-labeled phospholipid substrates under various conditions as given in the text. The rat brain iPLA2 was purified as described elsewhere (H.C. Yang et al., manuscript in preparation incorporated herein). Human recombinant cPLA2 was a gift from Drs. J.D. Sharp and R.M. Kramer at Lilly Laboratories. 1-[¹⁴C]Palmitoyl-sn-glycero-3-phosphorylcholine and 1-palmitoyl-2-[1-¹⁴C]palmitoyl-sn-glycerol-3-phosphorylcholine were purchased from Amersham. 1-Palmitoyl-2-[1-¹⁴C]arachidonoyl-sn-glycerol-3-phosphorylcholine was purchased from DuPont-NEN. All unlabeled phospholipids were purchased from Avanti Polar Lipids. Triton X-100 (TX-100) and PIP2 were obtained from CalBiochem.

2.6. Synthesis of plasmenylcholine

The sn-2 labeled PlsCho (plasmenylcholine or 1-O-(Z)-1 P -alkenyl-2-arachidonoyl-sn-glycero-3-phosphocholine) was synthesized as follows. A total of 4 µmol [1-¹⁴C]arachidonic acid (from NEN, with specific activity 63.3 µCi/µmol) was diluted 10 times with cold arachidonic acid in 250 µl distilled methylene chloride (Fisher Scientific). To this 0.04 mmol p(N,N-dimethyl)amino pyridine (Aldrich) and 0.08 mmol 1,3-dicyclohexyl carbodiimide (Aldrich) were added to yield the arachidonoyl anhydride upon 1 h of stirring.

Lysoplasmerylcholine (0.06 mmol, from Serdary) dissolved in 200 μ l methylene chloride and 50 μ l pyridine (Fisher Scientific) was added to the arachidonoyl anhydride solution with 0.03 μ mol dimethylaminopyridine and left stirring for 8 h. The reaction progress was monitored by thin layer chromatography (Merck) using a mobile phase of chloroform:methanol:triethyl amine:water (65:30: 1.5:3.5), and retardation factors were 0.6 and 0.2 for PlsCho and LysoPlsCho, respectively. The separation of the product was carried out by preparative layer chromatography (Merck) in the above mobile system. The reaction yielded a total of 3.6 mg (7.7 μ mol) of radiolabeled PlsCho (specific activity 0.18 μ Ci/ μ mol) by quantitative phosphate analysis.

2.7. Inhibition studies of hLysoPLA

Various concentrations of each inhibitor (BioMol) were prepared in DMSO. 5 μ l of each inhibitor was added to 480 μ l of LysoPC substrate (125 μ M Ly- soPC in the assay buffer). Enzyme (either mouse or human PLA) was added to the substrate-inhibitor mixture to start the reaction, which was incubated at 40°C for 30 min. Control experiments were performed with the same amount of enzyme with 5 μ l DMSO in the incubation mixture. The reversibility of the inhibition was tested by pre-incubation of the enzyme in the presence or absence of the inhibitor, followed by overnight dialysis in the assay buffer. The recovery of the enzyme activity as a function of time was then followed. Each data point represents an average of duplicates.

EXAMPLE 1.

Cloning and expression of hLysoPLA.

LysoPLA plays important roles in regulating the level of the multifunctional LysoPL, and several lines of evidence have suggested that LysoPLA exists in human. First, a relatively high level of LysoPLA activity has been found in human brain and it was proposed to be the major route by which LysoPL is removed from cell membranes [43]. Second, two human

LysoPLAs (molecular masses of 20 and 22 kDa) have been purified from human HL-60 cells [55]. These two enzymes appear to be the human isoforms of the mouse 27 and 28 kDa LysoPLAs. Third, when we searched DNA and protein databases in GenBank using mouse LysoPLA sequence information, several human cDNA clones were identified that match to
 5 different parts of the mouse gene Wang et al. / Biochimica et Biophysica Acta 1437 (1999) 157-169 with high homology. However, these cDNA sequences were obtained from different human tissues, their functions not identified, and none of them contained the entire protein sequence.

10 To determine the sequence of the human LysoPLA and to study the properties and functions of this enzyme in lipid metabolism and signal transduction, we have cloned this hLysoPLA using RT-PCR techniques. Normal human brain mRNA was used to generate the first-strand cDNA, from which a 700 bp product was amplified using primers corresponding to the N and C-terminals of hLysoPLA (Fig. 1). Then, the 700 bp DNA was ligated to the
 15 pCR2.1 vector and sequenced, as shown in Fig. 1 along with the translated protein sequences. The hLysoPLA is a single polypeptide composed of 230 amino acids with a calculated molecular mass of 25 kDa. The hLysoPLA sequence is highly homologous to the mouse/rat LysoPLA, 89% on the DNA level, and 92% on the protein level. The altered nucleotides and amino acids (shown in bold in Fig. 1) are spread out over the entire sequence, probably due to
 20 the random mutations of an ancestor enzyme during evolution. The Ser-119, Asp-174 and His-208 triad that forms the catalytic site for the mLysoPLA [46] is preserved in the human enzyme, indicating that the catalytic mechanism is also conserved.

To express hLysoPLA, *E. coli* transformed with the protein expression vector
 25 pET28a(+)/hLysoPLA was induced with 0.4 mM IPTG. SDS-PAGE analysis of cell homogenates showed that a 28 kDa protein band is strongly induced (lane 2 vs. lane 1 in Fig. 2). The recombinant protein was purified in two steps. The first was Ni-NTA chromatography

that removed the vast majority of the contamination proteins, and the second was G-75 chromatography that removed the minor high molecular weight contamination and exchanged the enzyme into a low salt buffer in which it is more stable. The hLysoPLA thus obtained was homogeneous as estimated by the SDS-PAGE (lane 3 in Fig. 2). The His-Tag at the N terminus of the protein was removed by thrombin, as shown in lane 4 of Fig. 2. The recombinant hLysoPLA thus obtained has an extra three amino acid residues (namely, Gly-Ser-His) at the N terminus. The specific activity of the recombinant hLysoPLA is about 1.3 $\mu\text{mol}/\text{min}/\text{mg}$ toward palmitoyl LysoPC, which is the same as the value reported for the 27 kDa mLysoPLA. This demonstrates that the sequence shown in Fig. 1 does indeed encode an active human LysoPLA.

EXAMPLE 2

Kinetic characterization of the recombinant hLysoPLA

To investigate the catalytic properties of the hLysoPLA, we first determined the specific activity of hLysoPLA as a function of substrate (1-palmitoyl LysoPC) concentration. As shown in Fig. 3, the catalytic activity exhibits saturation kinetics. However, the data did not fit well to the Michaelis-Menten equation (dotted line in Fig. 3). There seems to be some cooperativity, since the data fit to the Hill equation (solid line in Fig. 3) with $n = 1.53 \pm 0.08$, $k_{\text{cat}} = 1.34 \pm 0.04 \mu\text{mol}/\text{min}/\text{mg}$, and substrate at half-maximal saturation is $12.7 \pm 0.9 \mu\text{M}$. Furthermore, there is no dramatic increase in the enzyme activity near the cmc of the substrate ($7 \mu\text{M}$), indicating that the enzyme hydrolyzes both monomeric and micellar substrates. This suggests that hLysoPLA is not an interfacially activated enzyme.

TX-100 is often used in the purification and stabilization of membrane-associated proteins. In addition, it is used to change the surface concentration of the substrate in the mixed-micelle assay for mechanistic studies [56,57]. To determine the dependence of the enzyme activity on the substrate surface concentration, we measured the hLysoPLA activity

under two conditions:


(1) the bulk LysoPC concentration (1.125 mM) was kept constant and the TX- 100 concentration was varied (Fig. 4A);

(2) the bulk TX-100 concentration (1 mM) was kept constant and the LysoPC concentration was varied (Fig. 4B).

In both cases, enzyme activity increases as the percentage of LysoPC substrate in the micelles increases, and both sets of data fit well to the Michaelis-Menten equation with similar values of k_{cat} (1.6 $\mu\text{mol}/\text{min}/\text{mg}$ and 1.7 $\mu\text{mol}/\text{min}/\text{mg}$). These k_{cat} values are also very close to that obtained in Fig. 3, a result expected if TX-100 serves as a neutral surface diluter of the substrate.

In addition, we have carried out detailed kinetic measurements and analysis to test the surface dilution kinetic model and results are shown in Fig. 4°C. The experimental data were fitted globally to Eq. 1 derived from the model in which hLysoPLA follows the two-step binding kinetics (Scheme 1). That is, hLysoPLA (E) binds first to the mixed-micellar surface (S) and then to the LysoPC substrate (A) presented on the surface.

Scheme 1:



Equation 1:

$$v = \frac{V_{\max} [\text{LysoPC} + \text{TX-100}] \{\text{LysoPC}\}}{K_m K_s + K_m [\text{LysoPC} + \text{TX-100}] + [\text{LysoPC} + \text{TX-100}] \{\text{LysoPC}\}}$$

Here, [LysoPC+TX-100] is the total molar concentration in the bulk solution, and {LysoPC} is the molar fraction of the substrate on the mixed-micellar surface. Calculation of the amount of TX-100 in the micelle takes into account the amount of monomeric detergent in the solution, assuming the critical micelle concentration of TX-100 is 0.25 mM. The fitting parameter K_s represents the dissociation constant (k_{-1}/k_1) for the mixed-micellar surface, K_m represents the apparent Michaelis constant ($=(k_{-1}+k_2)/k_1$) on the surface, and V_{max} is the catalytic turnover rate. The values of parameters obtained from global fits are: $V_{max} = 1.37 \pm 0.05 \mu\text{mol}/\text{min}/\text{mg}$, $K_m = 12.2 \pm 0.9 \text{ mol}\%$ and $K_s = 66 \pm 7 \mu\text{M}$. These data are consistent with the following three conclusions.

First, the fact that a single value for K_s fits all the experimental data suggests that this enzyme binds to mixed-micelles with the same affinity regardless of the micellar composition. Thus, the first binding step is likely to occur through a non-specific hydrophobic interaction with the surface. Second, the enzyme appears to act primarily on the substrate within the interface. This conclusion is also supported by surface dilution kinetics observed in Fig. 4A and 4B. Third, the dependence of apparent V_{max} on mol% of LysoPC in the micelle is consistent with a single binding site for the substrate. This 1:1 stoichiometry of substrate-enzyme complex suggests that the apparent cooperativity seen in the kinetics of hLysoPLA on pure LysoPC micelles (Fig. 3) results from the change in the substrate presentation (monomers vs. premicellar aggregates vs. micelles) rather than a cooperative binding of two or more substrates to catalytic or allosteric sites.

EXAMPLE 3

Insignificant PLA2 activity of hLysoPLA

When we first purified the mouse LysoPLA from P388D1 cells, no other enzymatic activities (PLA1, PLA2, acyltransferase, transacylase and esterase) were found. Therefore, it

appears to be a LysoPL-specific LysoPLA . Similar results were obtained for the rat LysoPLA and the relative rates towards different LysoPL substrates were reported [Sugimoto et al., (1996) J. Biol. Chem. 271, 7705-11]. However, a recently sequenced rabbit enzyme that shares high sequence homology (approx. 97%) to the rat/ mouse LysoPLA was reported to have both PLA2 and LysoPLA activities [Portilla, et al., (1968) J.Am.Soc.Nephrol. 9, 1178-86]. The specific activities, however, were only 10 nmol/min/mg for PLA2 activity and 20 nmol/min/mg for LysoPLA activity. The PLA2 activity was also reported to be selective for PlsCho substrate with arachidonic acid at the sn2 position. To determine whether hLysoPLA also expresses PLA2 activity, we have explored its ability to hydrolyze arachidonic acid labeled PlsCho as well as other phospholipid substrates under a variety of conditions. As summarized in Table 1, hLysoPLA did not show any significant activity toward the PlsCho substrate labeled with [14 C]arachidonic acid, whether in mixed micelles or in vesicles. Also no PLA2 activity was found for hLysoPLA toward several phosphatidylcholine substrates.

As a control, LysoPLA activity toward LysoPC was determined at the same time with the same batch of enzyme. Since the hLysoPLA was active toward LysoPC, the insignificant PLA2 activity of hLysoPLA is not due to the inactivation of the enzyme. In comparison, cPLA2 (an arachidonic acid-selective PLA2) showed a relatively high activity toward PlsCho when the substrate was presented in the presence of 3 mol% PIP2, which is about 60% of its activity toward PAPC under the same conditions. Rat brain iPLA2 demonstrated a weak but significant activity toward PlsCho. It is 10- and 4-fold lower than its activity toward DPPC and PAPC TX-100 mixed micelles, respectively.

Because hLysoPLA did not show any significant activity toward any diradylglycerophospholipids (PlsCho, PAPC, DPPC) under all the conditions tested, the hLysoPLA is not a PLA2. In light of the high sequence homology among the mouse, rat and

human LysoPLAs, and the fact that these enzymes exhibited the same kinetic properties, we propose that these LysoPLAs, as a group, are specific LysoPLAs without other significant enzymatic activities. The rabbit enzyme was originally reported to be only a PLA2 without any significant LysoPLA activity [Portilla et al., (1996) J. Biol. Chem. 271, 15451-57], and only recently was the LysoPLA activity found after the enzyme showed high sequence homology to the rat/mouse LysoPLA. The specific activity of the rabbit enzyme as a LysoPLA, however, was more than 50-fold lower than the specific activity of the corresponding mouse, rat and human enzymes under similar assay conditions. We have found several factors that can reduce the LysoPLA activity significantly and may contribute to the lower LysoPLA observed for the rabbit enzyme. For example, LysoPLA appears to be quite unstable and the temperature/solution components of the enzyme during purification, storage and assay affect its activity substantially. The percentage of hydrolysis and linearity of the reaction also need to be considered when the activity is determined from a single time point measurement. Because of the sequence homology between the rabbit enzyme and the human, rat and mouse LysoPLAs, the rabbit enzyme may be a LysoPL-specific LysoPLA as well.

EXAMPLE 4

Inhibition of the LysoPLA

Several small organic compounds were examined for their abilities to inhibit the mouse and human LysoPLA, and similar results were found for both enzymes. PACOCF₃ and BEL are iPLA2 inhibitors, but neither of them inhibited the LysoPLA activity well. LysoPAF, a LysoPC substrate analog with an ether linkage in the sn-1 position, was not a good inhibitor either. MAFP is an inhibitor of both iPLA2 and cPLA2. Here, we found that it also inhibited LysoPLA with an apparent IC₅₀ of 0.6 μ M (Fig. 5). The inhibition of LysoPLA by MAFP is irreversible, since LysoPLA remained inactive when the enzyme and MAFP mixture was assayed after overnight dialysis. The inhibition of LysoPLA by MAFP is most likely due to the covalent modification of the enzyme at the active site Ser-119. MAFP has

Table I. Substrate selectivity of lysophospholipase compared with cPLA₂ and iPLA₂ toward plasmenyolphosphatidylcholine and phosphatidylcholine under various conditions. As a control, LysoPLA activity toward the LysoPC substrate was also included.

Enzyme	Substrate	Assay conditions	Activity ($\mu\text{mol}/\text{min}/\text{mg}$)
Human Recombinant LysoPLA	LysoPC micelles (125 μM)	100 mM Tris, pH 8.0, 10 mM βMe	1.13 \pm 0.03
	PlsCho/TX-100 mixed micelles (100 μM : 600 μM)	100 mM Hepes, pH 7.5, 10 mM βMe	0.0024 \pm 0.0004
	PlsCho sonicated vesicles (100 μM)	100 mM Tris, pH 8.0, 4 mM EGTA, 10 mM βMe	0.0009 \pm 0.0003
	PlsCho sonicated vesicles (100 μM)	100 mM Tris, pH 8.0, 150 mM NaCl, 3 mM MgCl_2 , 10 mM βMe	0.0006 \pm 0.0002
	DPPC/TX-100 mixed micelles (100 μM : 400 μM)	100 mM Hepes, pH 7.5, 2 mM DTT, 5 mM EDTA	<0.0001
	DPPC/POPS sonicated vesicles (67 μM : 33 μM)	100 mM Hepes, pH 7.5, 5 mM EDTA or Ca^{2+} , 1 mg/ml BSA	<0.0001
	PAPC/TX-100 mixed micelles (100 μM : 400 μM)	100 mM Hepes, pH 7.5, 80 μM Ca^{2+} , 2 mM DTT, 0.1 mg/ml BSA	<0.0001
Human Recombinant cPLA ₂	PAPC/PIP ₂ /TX-100 mixed micelles (97 μM : 3 μM : 400 μM)	100 mM Hepes, pH 7.5, 80 μM Ca^{2+} , 2 mM DTT, 0.1 mg/ml BSA	<0.0001
	PlsCho/PIP ₂ /TX-100 mixed micelles (100 μM : 3 μM : 600 μM)	100 mM Hepes, pH 7.5, 80 μM Ca^{2+} , 0.1 mg/ml BSA, 2 mM DTT.	13.58 \pm 0.05
Rat brain iPLA ₂	PAPC/PIP ₂ /TX-100 mixed micelles (97 μM : 3 μM : 400 μM)	100 mM Hepes, pH 7.5, 80 μM Ca^{2+} , 0.1 mg/ml BSA, 2 mM DTT.	21.81 \pm 0.09
	PlsCho/TX-100 mixed micelles (100 μM : 600 μM)	100 mM Hepes, pH 7.5, 5 mM EDTA, 2 mM DTT	0.53 \pm 0.03
	DPPC/TX-100 mixed micelles (100 μM : 400 μM)	100 mM Hepes, pH 7.5, 5 mM EDTA, 2 mM DTT	5.6 \pm 0.2
	PAPC/TX-100 mixed micelles (100 μM : 400 μM)	100 mM Hepes, pH 7.5, 5 mM EDTA, 2 mM DTT	2.0 \pm 0.04

been used in signal transduction studies as a selective cPLA2 inhibitor. However, as it also inhibits both LysoPLA and iPLA2 activities, the contribution of each of these enzymes to signal transduction should be more carefully considered.

EXAMPLE 5

Tissue distribution of hLysoPLA

To examine the tissue distribution pattern of LysoPLA, we have carried out Northern and Western blots using either the human LysoPLA gene as a Northern blot probe, or the rabbit antibody raised against pure recombinant hLysoPLA. As shown in Fig. 6A, the size of hLysoPLA messenger is about 2.4 kb. The mRNA is widely distributed in many tissues, with heart, placenta and skeletal muscle being the most abundant ones, followed by liver, pancreas, kidney, brain and lung. On the Northern master blot which has messengers from more tissues (Fig. 6B,C), similar patterns were observed though the relative intensity for a few tissues was changed compared to Fig. 6A. In Fig. 6B,C, placenta and testis are the most abundant sources for hLysoPLA, followed by adrenal and salivary glands, liver, heart, skeletal muscle, and trachea colon. In contrast to the mRNA levels in adult tissues, the fetal mRNA of hLysoPLA appears to be much more uniform among different tissues. To screen the expression of hLysoPLA in different tissues, Western analysis was performed with rabbit polyclonal antibody for the hLysoPLA. As shown in Fig. 6D, testis expressed the most abundant hLysoPLA, followed by kidney, brain, placenta, liver, heart and ovary.

DISCUSSION

These examples define a new, cloned, expressed and characterized human lysophospholipid-specific LysoPLA. The enzyme is widely distributed in almost all tissues at both mRNA and protein levels, although the relative amount varies greatly from tissue to tissue. The human LysoPLA is homologous to the rat, mouse and rabbit enzymes, with the catalytic triad conserved in all and the changed residues spread randomly along the protein

sequences. The mouse and human enzymes exhibit similar inhibition patterns toward various inhibitors, with MAFP being the most potent one. Detailed kinetic analysis shows that the human LysoPLA displays apparent co-operativity and surface dilution kinetics. The enzyme appears to bind nonspecifically to the mixed-micellar surface first, followed by the specific
5 binding to the substrate on the surface.

The kinetic parameters associated with this surface dilution kinetic model were determined, and it appears that hLysoPLA has a single substrate binding site and a surface nonspecific recognition site. The apparent co-operativity is likely due to the change of
10 substrate presentation. In addition, the hLysoPLA did not display any significant PLA2 activity toward PlsCho and phosphatidylcholine in both mixed-micelle and vesicle forms. Since no significant PLA1, PLA2, acyltransferase, transacylase and esterase activities were found for rat and mouse LysoPLA, we conclude that these enzymes form a group of specific LysoPLAs that recognize and act on only lysophospholipids.

Lysophospholipases are critical enzymes that act on biological membranes to regulate the multifunctional lysophospholipids; increased levels of lysophospholipids are associated with a host of diseases. The instant invention describes the cDNA cloning of a human brain
15 25 kDa lysophospholipid-specific lysophospholipase (hLysoPLA).

The enzyme (at both mRNA and protein levels) is widely distributed in tissues, but with quite different abundances. The hLysoPLA hydrolyzes lysophosphatidylcholine in both monomeric and micellar forms, and exhibits apparent cooperativity and surface dilution kinetics, but not interfacial activation. Detailed kinetic analysis indicates that the hLysoPLA
20 25 binds first to the micellar surface and then to the substrate presented on the surface. The kinetic parameters associated with this surface dilution kinetic model are reported, and it is concluded that hLysoPLA has a single substrate binding site and a surface recognition site.

The apparent cooperativity observed is likely due to the change of substrate presentation. In contrast to many nonspecific lipolytic enzymes that exhibit lysophospholipase activity, hLysoPLA hydrolyzes only lysophospholipids and has no other significant enzymatic activity. Of special interest, hLysoPLA does not act on plasmenylcholine. Of the several inhibitors
5 tested, only methyl arachidonyl fluorophosphonate (MAFP) potently and irreversibly inhibits the enzymatic activity. The inhibition by MAFP is consistent with the catalytic mechanism proposed for the enzyme - a serine hydrolase with a catalytic triad composed of Ser-119, Asp-174 and His-208.

10 While the present invention has now been described in terms of certain preferred embodiments, and exemplified with respect thereto, one skilled in the art will readily appreciate that various modifications, changes, omissions and substitutions may be made without departing from the spirit thereof. It is intended, therefore, that the present invention be limited solely by the scope of the following claims.

CLAIMS

What is claimed is:

1. A cDNA segment encoding a lysophospholipid-specific human brain
5 lysophospholipase enzyme protein molecule, comprising:
a segment of 690 deoxyribonucleotide base pairs from position 448 to position
741 in Figure 1.
2. A deoxyribonucleic acid sequence for a cDNA segment encoding a
10 lysophospholipid-specific human brain lysophospholipase enzyme protein molecule,
comprising:
a sequence of 690 deoxyribonucleotide base pairs from position 448 to
position 741 in Figure 1.
- 15 3. A recombinant lysophospholipid-specific human brain lysophospholipase
enzyme protein molecule, comprising:
a single 25 kDa polypeptide having 230 amino acid residues; and
a catalytic activity site triad at Ser-119, Asp-174 and His-208.
- 20 4. An amino acid residue sequence for a recombinant lysophospholipid-specific
human brain lysophospholipase enzyme protein molecule, comprising:
amino acid residues from amino acid residue position 1 to amino acid residue
position 230 in Figure 1.
- 25 5. A method for inhibiting catalytic activity of a recombinant lysophospholipid-
specific human brain lysophospholipase enzyme protein molecule, comprising:

..

..

exposing the lysophospholipase enzyme protein molecule to a solution
containing methyl arachidonyl fluorophosphates.

6. The method for inhibiting catalytic activity according to claim 5, wherein the
inhibiting resulting from the exposing is irreversible.

5

7. A method for treating patients with diseases caused by increased levels of
lysophospholipids, comprising:

Supplying a recombinant lysophospholipid-specific lysophospholipase
enzyme to an enzyme deficient patient.

10

8. The method for treating patients according to claim 7, wherein the supplying
transpires by infusion.

9. The method for treating patients according to claim 7, wherein the supplying
transpires by gene augmentation therapy.

15

20

25

ABSTRACT

A cloned of a human brain lysophospholipid-specific lysophospholipase enzyme molecule, its potential use for treatment of a host of diseases and method of inactivation are disclosed. Also disclosed are its distribution in tissue sand detailed kinetic analysis. hLysoPLA has a single substrate binding site and a surface recognition site. In contrast to many nonspecific lipolytic enzymes that exhibit lysophospholipase activity, hLysoPLA hydrolyzes only lysophospholipids and has no other significant enzymatic activity.




Fig 2.

LysopC (μM)




Fig 3




Fig 4A




Fig 4B




FIG 4C




Fig 5




FIG 6A




FIG 6B

C

	1	2	3	4	5	6	7	8
A	Whole Brain (8.0)	amygdala (5.0)	caudate nucleus (5.8)	cerebellum (18.0)	cerebral cortex (4.4)	frontal lobe (4.0)	hippocampus (9.6)	medulla oblongata (5.0)
B	occipital lobe (10.2)	putamen (9.2)	substantia nigra (10.9)	temporal lobe (6.7)	thalamus (17.0)	subthalamic nucleus (14.4)	spinal cord (11.2)	
C	heart (42.4)	aorta (10.7)	skeletal muscle (41.9)	colon (36.3)	bladder (17.9)	uterus (14.6)	prostate (30.8)	stomach (43.4)
D	testis (83.3)	ovary (10.8)	pancreas (31.9)	pituitary gland (16.3)	adrenal gland (46.5)	thyroid gland (25.6)	salivary gland (48.8)	mammary gland (22.8)
E	kidney (29.4)	liver (42.8)	small intestine (29.8)	spleen (31.0)	thymus (23.0)	peripheral leukocyte (21.2)	lymph node (23.0)	bone marrow (12.7)
F	appendix (15.0)	lung (21.8)	trachea (34.9)	placenta (100.0)				
G	fetal brain (18.4)	fetal heart (38.4)	fetal kidney (51.5)	fetal liver (47.7)	fetal spleen (55.5)	fetal thymus (26.9)	fetal lung (42.4)	
H	yeast total RNA 100ng	yeast tRNA 100 ng	<i>E. coli</i> rRNA 100ng	<i>E. coli</i> DNA 100 ng	Poly r(A) 100ng	human COT1 DNA 100ng	human DNA 100 ng (3.4)	human DNA 500 ng (8.8)

Fig 6c

bioRxiv preprint doi: <https://doi.org/10.1101/111111>; this version posted January 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Fig 6D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY
(Page 1 of 2)

EACH OF THE APPLICANTS SIGNING BELOW HEREBY DECLARES THAT:

My residence, post office address, and citizenship are as stated next to my name in PART A on page 2 hereof.

I believe that I am an original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **CLONED HUMAN LYSOPHOSPHOLIPASE**, the specification of which is attached hereto.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent(s) issued thereon.

See next page 2 attached, signed, and made a part hereof.

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY
(Page 2 of 2)

I hereby appoint as my attorney with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

William C. Fuess Registration Number 30,054

whose mailing address for this application is:

FUESS & DAVIDENAS
Attorneys at Law
10951 Sorrento Valley Road, Suite II-G
San Diego, California 92121-1613
Attention: William C. Fuess

and whose telecommunications numbers are:

Telephone: (619) 452-8293
Facsimile: (619) 452-8293

All correspondence and telephone calls should be directed to William C. Fuess at the address and telephone number referenced above.

PART A: Inventors' Information and Signatures

Full Name of First Inventor: Edward A. Dennis
Citizenship: U.S.A.

Residence Address: 1921 Hypatia Way
La Jolla, CA 92037

Inventor's Signature: Edward A. Dennis

Date: 1/28/00

Full Name of First Inventor: AIJUN WANG
Citizenship: U.S.A.

Residence Address: _____

Inventor's Signature: _____

Date: _____

See page 1 to which this page is attached and of which this page is a part.

SEQUENCE LISTING

<110> Regents, University of California

<120> Human Lysophospholipase

<130> Human Lysophospholipase

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 758

<212> DNA

<213> Homo sapiens

<300>

<301> Wang, Aijun

Yang, Hsiu-Chiung

Friedman, Peter

Johnson, Christina A.

Dennis, Edward A.

<302> A Specific Human Lysophospholipase: cDNA Cloning,
Tissue Distribution and Kinetic Characterization

<303> Biochim. Biophys. Acta

<304> 1437

<306> 157-169

<307> 1999

<400> 1

at gtgcggcaat 60

aacatgtcaa ccccgctgcc cgccatcgtg cccgccgccc ggaaggccac cgctgcggtg 120

atcttctctgc atggattggg agatactggg cacggatggg cagaagcctt tgcaggtatc 180

agaagttcac atatcaaata tatctgcccg catgcgcctg ttaggcctgt tacattaaat 240

atgaacgtgg ctatgccttc atggtttgat attattgggc tttcaccaga ttcacaggag 300

gatgaatctg ggattaaaca ggcagcagaa aatataaaag ctttgattga tcaagaagtg 360

aagaatggca ttccttctaa cagaattatt ttgggagggg tttctcaggg aggagcttta 420

tctttatata ctgcccttac cacacagcag aaactggcag gtgtcactgc actcagttgc 480

tggcttcacac ttcgggcttc cttccacag ggtcctatcg gtggtgctaa tagagatatt 540

tctattctcc agtgccacgg ggattgtgac cctttggttc ccctgatgtt tggttctctt 600

acgggtggaaa aactaaaaac attggtgaat ccagccaatg tgacctttaa aacctatgaa 660

ggtatgatgc acagttcgtg tcaacaggaa atgatggatg tcaagcaatt cattgataaa 720

ctcctacctc caattgattg acgtcactaa gaggcctt 758

SEQUENCE LISTING

<110> Regents, University of California

<120> Human Lysophospholipase

<130> Human Lysophospholipase

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> ~~758~~ 690

<212> DNA

<213> Homo sapiens

<300>

<301> Wang, Aijun
Yang, Hsiu-Chiung
Friedman, Peter
Johnson, Christina A.
Dennis, Edward A.

<302> A Specific Human Lysophospholipase: cDNA Cloning,
Tissue Distribution and Kinetic Characterization

<303> Biochim. Biophys. Acta

<304> 1437

<306> 157-169

<307> 1999

<400> 1

at gtgcggcaat 60

```
aacatgtcaa ccccgctgcc cgccatcgtg cccgccgccc ggaaggccac cgctgcggtg 120
attttcctgc atggattggg agatactggg cacggatggg cagaagcctt tgcaggtatc 180
agaagttcac atatcaaata tatctgcccg catgcgctg ttaggcctgt tacattaaat 240
atgaacgtgg ctatgccttc atggtttgat attattgggc tttcaccaga ttcacaggag 300
gatgaatctg ggattaaaca ggcagcagaa aatataaaag ctttgattga tcaagaagtg 360
aagaatggca ttccttctaa cagaattatt ttgggagggt tttctcaggg aggagcttta 420
tctttatata ctgcccttac cacacagcag aaactggcag gtgtcactgc actcagttgc 480
tggcttccac ttcgggcttc ccttccacag ggtcctatcg gtggtgctaa tagagatatt 540
tctattctcc agtgccacgg ggattgtgac cctttggttc ccctgatgtt tggttctctt 600
acggtgga aaactaaaaac attggtgaat ccagccaatg tgacctttaa aacctatgaa 660
ggtatgatgc acagttcgtg tcaacaggaa atgatggatg tcaagcaatt cattgataaa 720
ctcctacctc caattgattg acgtcactaa gaggcctt 758
```

<210> 2
<211> 230
<212> PRT
<213> Homo sapiens

<400> 2

```
Met Cys Gly Asn Asn Met Ser Thr Pro Leu Pro Ala Ile Val Pro Ala
 1          5          10          15

Ala Arg Lys Ala Thr Ala Ala Val Ile Phe Leu His Gly Leu Gly Asp
          20          25          30

Thr Gly His Gly Trp Ala Glu Ala Phe Ala Gly Ile Arg Ser Ser His
          35          40          45

Ile Lys Tyr Ile Cys Pro His Ala Pro Val Arg Pro Val Thr Leu Asn
          50          55          60

Met Asn Val Ala Met Pro Ser Trp Phe Asp Ile Ile Gly Leu Ser Pro
          65          70          75          80

Asp Ser Gln Glu Asp Glu Ser Gly Ile Lys Gln Ala Ala Glu Asn Ile
          85          90          95

Lys Ala Leu Ile Asp Gln Glu Val Lys Asn Gly Ile Pro Ser Asn Arg
          100          105          110

Ile Ile Leu Gly Gly Phe Ser Gln Gly Gly Ala Leu Ser Leu Tyr Thr
          115          120          125

Ala Leu Thr Thr Gln Gln Lys Leu Ala Gly Val Thr Ala Leu Ser Cys
          130          135          140

Trp Leu Pro Leu Arg Ala Ser Leu Pro Gln Gly Pro Ile Gly Gly Ala
          145          150          155          160

Asn Arg Asp Ile Ser Ile Leu Gln Cys His Gly Asp Cys Asp Pro Leu
          165          170          175

Val Pro Leu Met Phe Gly Ser Leu Thr Val Glu Lys Leu Lys Thr Leu
          180          185          190

Val Asn Pro Ala Asn Val Thr Phe Lys Thr Tyr Glu Gly Met Met His
          195          200          205

Ser Ser Cys Gln Gln Glu Met Met Asp Val Lys Gln Phe Ile Asp Lys
          210          215          220

Leu Leu Pro Pro Ile Asp
          225          230
```